Speke Resort & Conference Centre Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2012
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Drug Resistance and Persistence in Tuberculosis (E1)
Organizer(s) Ann M. Ginsberg and John D. McKinney
May 13—18, 2012
Speke Resort & Conference Centre • Kampala, Uganda
Abstract Deadline: Jan 13, 2012
Late Abstract Deadline: Feb 14, 2012
Scholarship Deadline: Jan 13, 2012
Early Registration Deadline: Mar 16, 2012
Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation. Sponsored by GlaxoSmithKline
Summary of Meeting:
According to the World Health Organization, over 25% of new tuberculosis cases in some subnational regions are multi-drug-resistant TB (MDR-TB) and, as of March 2010, 58 countries had reported XDR-TB (TB resistant to the major classes of both first- and second-line drugs). The Keystone Symposia meeting on Drug Resistance and Persistence in Tuberculosis aims to bring together basic and clinical researchers and public health experts from diverse backgrounds to explore the following: 1) the fundamental biology underlying genetic and phenotypic drug-resistance in TB; 2) progress in expanding capacity in high-burden settings to perform drug susceptibility testing; 3) identification of novel drug targets; 4) innovative strategies for drug discovery; and 5) advances in developing multi-drug regimens that will be effective against currently drug-resistant as well as drug-sensitive strains of M. tuberculosis. Investigators from outside the TB field will be included to provide new perspectives and stimulate fresh approaches for tackling this global public health priority.
View Scholarships/Awards
According to the World Health Organization, over 25% of new tuberculosis cases in some subnational regions are multi-drug-resistant TB (MDR-TB) and, as of March 2010, 58 countries had reported XDR-TB (TB resistant to the major classes of both first- and second-line drugs). The Keystone Symposia meeting on Drug Resistance and Persistence in Tuberculosis aims to bring together basic and clinical researchers and public health experts from diverse backgrounds to explore the following: 1) the fundamental biology underlying genetic and phenotypic drug-resistance in TB; 2) progress in expanding capacity in high-burden settings to perform drug susceptibility testing; 3) identification of novel drug targets; 4) innovative strategies for drug discovery; and 5) advances in developing multi-drug regimens that will be effective against currently drug-resistant as well as drug-sensitive strains of M. tuberculosis. Investigators from outside the TB field will be included to provide new perspectives and stimulate fresh approaches for tackling this global public health priority.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
SUNDAY, MAY 13
MONDAY, MAY 14
TUESDAY, MAY 15
WEDNESDAY, MAY 16
THURSDAY, MAY 17
FRIDAY, MAY 18
Conference Program Print | View meeting in 12 hr (am/pm) time
SUNDAY, MAY 13
19:15—20:30
Welcome and Keynote Address
Virander Singh Chauhan,
International Centre for Genetic Engineering and Biotechnology, India
MDR TB: How to Deal with a Major Global Health Challenge?
MDR TB: How to Deal with a Major Global Health Challenge?
09:00—12:15
Mechanisms of Drug Resistance (Including Lessons from Other Fields)
*
Eric J. Rubin,
Harvard T.H. Chan School of Public Health, USA
Valerie Mizrahi,
University of Cape Town, South Africa
Mechanisms Driving Mutations to Drug Resistance
Mechanisms Driving Mutations to Drug Resistance
Sébastien Gagneux,
Swiss Tropical and Public Health Institute, Switzerland
The Fitness Cost of Drug Resistance
The Fitness Cost of Drug Resistance
Vikram Saini,
University of Alabama, Birmingham, USA
Short Talk: Next-Generation Sequencing and Analysis of Cigarette Smoke-Induced Drug Resistant Mycobacterium tuberculosis Strains: Discovery of a Cigarette Smoke Signature
Short Talk: Next-Generation Sequencing and Analysis of Cigarette Smoke-Induced Drug Resistant Mycobacterium tuberculosis Strains: Discovery of a Cigarette Smoke Signature
Nataly Alvarez,
Corporation for Biological Research, Colombia
Short Talk: The Structural Modeling of the Interaction between Levofloxacin and the Mycobacterium tuberculosis Gyrase Catalytic Site Sheds Light on the Mechanisms of Fluoroquinolones Resistant tuberculosis in Colombian Clinical Isolates
Short Talk: The Structural Modeling of the Interaction between Levofloxacin and the Mycobacterium tuberculosis Gyrase Catalytic Site Sheds Light on the Mechanisms of Fluoroquinolones Resistant tuberculosis in Colombian Clinical Isolates
16:00—18:00
Future of the MDR/XDR Epidemic: Progress in Diagnosis of Drug-Resistant TB
*
David Alland,
Rutgers University, New Jersey Medical School, USA
Megan Murray,
Harvard Medical School, USA
Approaches to Understanding the Epidemic Dynamics of Drug Resistant TB
Approaches to Understanding the Epidemic Dynamics of Drug Resistant TB
Chris Gilpin,
World Health Organization, Switzerland
The Global Laboratory Initiative: Needs and Progress in Laboratory Infrastructure
The Global Laboratory Initiative: Needs and Progress in Laboratory Infrastructure
Philippe Jacon,
FIND (Foundation for Innovative New Diagnostics), Switzerland
Progress in Developing Point-of-Treatment Methods for Drug Susceptibility Testing: What’s on the Horizon?
Progress in Developing Point-of-Treatment Methods for Drug Susceptibility Testing: What’s on the Horizon?
David Alland,
Rutgers University, New Jersey Medical School, USA
09:00—12:00
Persistence (Phenotypic Drug Resistance) - Including Examples from Other Fields
John D. McKinney,
Swiss Federal Institute of Technology (EPFL), Switzerland
Individuality of Bacterial Responses to Antibiotics
Individuality of Bacterial Responses to Antibiotics
X. Sunney Xie,
Peking University, China
Persistence in Escherichia coli
Persistence in Escherichia coli
Natalie Balaban,
Hebrew University, Israel
Noise Amplification and Persistence
Noise Amplification and Persistence
Brian Weinrick,
Trudeau Institute, USA
Short Talk: A Persistence-Enhancing Transcriptional Program Coordinated by whiB6
Short Talk: A Persistence-Enhancing Transcriptional Program Coordinated by whiB6
Heather L. Torrey,
Northeastern University, USA
Short Talk: Analysis of High-Persister Strains in Mycobacterium tuberculosis
Short Talk: Analysis of High-Persister Strains in Mycobacterium tuberculosis
Cyrielle I. Kint,
University of Leuven, Belgium
Short Talk: Structure-Function Analysis of an Essential GTPase Involved in Bacterial Persistence
Short Talk: Structure-Function Analysis of an Essential GTPase Involved in Bacterial Persistence
Veerle R. Liebens,
University of Leuven, Belgium
Short Talk: New Insight into an Old Phenomenon: Extracellular Properties Determine Fluoroquinolone Tolerance in Pseudomonas aeruginosa
Short Talk: New Insight into an Old Phenomenon: Extracellular Properties Determine Fluoroquinolone Tolerance in Pseudomonas aeruginosa
17:00—19:00
Progress in TB Drug Discovery
Eric J. Rubin,
Harvard T.H. Chan School of Public Health, USA
Overview of Current and Future Approaches to TB Drug Discovery
Overview of Current and Future Approaches to TB Drug Discovery
Oren Zimhony,
Kaplan Medical Center affiliated to the school of Medicine Hebrew Universit, Israel
The Challenge of Pyrazinamide: Dissecting "Mechanism" between Sterilizing Effect, Conditions for Susceptibility and Site of Action
The Challenge of Pyrazinamide: Dissecting "Mechanism" between Sterilizing Effect, Conditions for Susceptibility and Site of Action
Claude Kirimuhuzya,
Kampala International University-Western Campus, Uganda
Short Talk: Eficacy of Uganda’s Plants on Rifampicin-Resistant Tuberculosis: A Review of Research Done in Uganda since 2006
Short Talk: Eficacy of Uganda’s Plants on Rifampicin-Resistant Tuberculosis: A Review of Research Done in Uganda since 2006
09:00—12:00
Novel Approaches to TB Drug Discovery
Gilla Kaplan,
Bill & Melinda Gates Foundation, USA
Immunomodulatory Molecules as Adjuvant Chemotherapy for TB
Immunomodulatory Molecules as Adjuvant Chemotherapy for TB
Kanury V. S. Rao,
International Centre for Genetic Engineering and Biotechnology, India
Elucidating the Crosstalk Mechanisms that Facilitate Intra-Macrophage Survival of Mycobacterium tuberculosis
Elucidating the Crosstalk Mechanisms that Facilitate Intra-Macrophage Survival of Mycobacterium tuberculosis
Priscille Marie Brodin,
CIIL Institut Pasteur, France
High Content Screening of M. tuberculosis Infected Macrophage as a Pre-Clinical Model for the Development of Novel Anti-Tuberculosis Drug Candidates
High Content Screening of M. tuberculosis Infected Macrophage as a Pre-Clinical Model for the Development of Novel Anti-Tuberculosis Drug Candidates
John Szumowski,
University of Washington, USA
Macrophage-Induced, Bacterial Efflux Pump-Mediated Drug Tolerance in Tuberculosis
Macrophage-Induced, Bacterial Efflux Pump-Mediated Drug Tolerance in Tuberculosis
Melanie Grobbelaar,
University of Stellenbosch Faculty of Health Sciences, South Africa
Short Talk: Adaptation of the Mycobacterium tuberculosis Transcriptome in Response to Rifampicin
Short Talk: Adaptation of the Mycobacterium tuberculosis Transcriptome in Response to Rifampicin
16:00—18:00
Novel Drug Targets
*
Lawrence Geiter,
Otsuka Pharmaceutical Development and Commercialization Inc., USA
Zhenkun Ma,
Global Alliance for TB Drug Development, USA
Target-Based Approach in Tuberculosis Drug Discovery
Target-Based Approach in Tuberculosis Drug Discovery
Graham F. Hatfull,
University of Pittsburgh, USA
Exploration and Exploitation of Mycobacteriophages
Exploration and Exploitation of Mycobacteriophages
Katarina Mikusova,
Comenius University, Faculty of Natural Sciences, Slovakia
DprE1 – Past, Present and Future
DprE1 – Past, Present and Future
Yap J. B. Boum II,
Epicentre Mbarara Research Base, Uganda
Short Talk: Thymidylate Synthase ThyX: An Excellent Target for New Anti-Tuberculosis Drugs
Short Talk: Thymidylate Synthase ThyX: An Excellent Target for New Anti-Tuberculosis Drugs
09:00—12:00
Updates on Progress in Developing Novel TB Treatments for M(X)XDR-TB
Myriam Haxaire,
Tibotec BVBA, Belgium
TMC207 Clinical Development Status
TMC207 Clinical Development Status
Lawrence Geiter,
Otsuka Pharmaceutical Development and Commercialization Inc., USA
Clinical Development of Delamanid (OPC-67683)
Clinical Development of Delamanid (OPC-67683)
Derek J. Sloan,
Malawi Liverpool Wellcome Trust Clinical Research Programme, Malawi
Short Talk: Bacillary Elimination Rates, Persister Phenotypes and Clinical Outcomes in a Longitudinal Study of TB Treatment in Malawi
Short Talk: Bacillary Elimination Rates, Persister Phenotypes and Clinical Outcomes in a Longitudinal Study of TB Treatment in Malawi
Umesh D. Gupta,
National Jalma Institute for Leprosy and Other Mycobacterial Diseases, India
Short Talk: Mycobacterium indicus pranii as a Stand-Alone or Adjunct Immunotherapeutic in Treatment of Experimental Animal Tuberculosis
Short Talk: Mycobacterium indicus pranii as a Stand-Alone or Adjunct Immunotherapeutic in Treatment of Experimental Animal Tuberculosis
Ann M. Ginsberg,
Bill & Melinda Gates Foundation, USA
The Ultimate Weapon Against Resistance and Persistence: Progress in Development of New TB Vaccines
The Ultimate Weapon Against Resistance and Persistence: Progress in Development of New TB Vaccines
17:00—19:00
Late-Breaking Session
*
John D. McKinney,
Swiss Federal Institute of Technology (EPFL), Switzerland
Sarah M. Fortune,
Harvard TH Chan School of Public Health, USA
Mutation Rate/Evolution of Drug Resistance Project
Mutation Rate/Evolution of Drug Resistance Project
Mike R. Barer,
University of Leicester, UK
Evidence for Persistent Bacteria in Sputa of Antibiotic-Treated TB Patients
Evidence for Persistent Bacteria in Sputa of Antibiotic-Treated TB Patients
Pierre Ankomah,
Emory University, USA
Short Talk: Two-Drug Antimicrobial Chemotherapy: A Mathematical Model and Experiments with Mycobacterium marinum
Short Talk: Two-Drug Antimicrobial Chemotherapy: A Mathematical Model and Experiments with Mycobacterium marinum
Juan Manuel Belardinelli,
Colorado State University, USA
Short Talk: Mutations in the beta-Hydroxyacyl ACP Dehydratase Confer Resistance to Thiacetazone in M. tuberculosis and M. kansasii
Short Talk: Mutations in the beta-Hydroxyacyl ACP Dehydratase Confer Resistance to Thiacetazone in M. tuberculosis and M. kansasii
Elizabeth Maria Streicher,
Stellenbosch University, South Africa
Short Talk: Mycobacterium tuberculosis Population Structure Determines the Outcome of Genetic Based Second-Line Drug Resistance Testing
Short Talk: Mycobacterium tuberculosis Population Structure Determines the Outcome of Genetic Based Second-Line Drug Resistance Testing
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
